SCHEMBL3247111

SCHEMBL3247111

Cc1cccc(S(=O)(=O)NCC(=O)Nc2ccc(Cl)cc2Cc2ccccc2Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.48
FLT4 P35916 1/20 0.48
KDR P35968 1/20 0.48
KAT6A Q92794 2/20 0.45
ALDH1A1 P00352 7/20 0.44
LMNA P02545 4/20 0.44
MAPT P10636 4/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HTT P42858 1/20 0.43
BACE1 P56817 1/20 0.43
TSHR P16473 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3251190 0.92 ALDH1A1 (0.46) ALDH1A1LMNAMAPTKMT2AMEN1
SCHEMBL3249160 0.90 ALDH1A1 (0.53) FLT1FLT4KDRALDH1A1LMNA
SCHEMBL4860809 0.88 L3MBTL1 (0.46) ALDH1A1LMNAMAPTKMT2AMEN1
SCHEMBL3253246 0.88 MEP1B (0.48) FLT1FLT4KDRALDH1A1LMNA
SCHEMBL3255565 0.88 MEP1B (0.55) FLT1FLT4KDRALDH1A1LMNA
SCHEMBL3255473 0.87 ALDH1A1 (0.47) FLT1FLT4KDRALDH1A1LMNA
SCHEMBL3252246 0.86 ALDH1A1 (0.62) ALDH1A1LMNAMAPTKMT2AMEN1
SCHEMBL4869124 0.86 GAA (0.44) ALDH1A1LMNAMAPTKMT2AMEN1
SCHEMBL4871474 0.85 FLT1 (0.52) FLT1FLT4KDRALDH1A1LMNA
SCHEMBL3244433 0.84 PTGES (0.44) FLT1FLT4KDRALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 FLT1 3361/4885FLT4 4260/4885KDR 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.